| Document |
Document Title |
|
WO/2024/046168A1 |
Provided are a Lactobacillus brevis strain and anti-cervical cancer use thereof. The provided Lactobacillus brevis is specifically (Lactobacillus brevis) YNH, which is deposited under CGMCC No. 24368 at the China General Microbiological ...
|
|
WO/2024/050517A1 |
This invention relates to methods of producing reprogrammed B cells, methods of treating cancer, and methods of enhancing an immune response in a subject having, suspected to have and/or at risk of cancer. The invention further relates t...
|
|
WO/2024/050342A1 |
Methods of treating prostate cancer, including castration-resistant prostate cancer and metastatic castration-resistant prostate cancer, comprising administering an effective amount of an androgen receptor (AR) antagonist and an effectiv...
|
|
WO/2024/050399A1 |
Single-domain antibodies that specifically bind human papillomavirus (HPV) E6 or E7 oncogenic peptides in complex with human major histocompatibility complex (MHC) proteins are described. The E6-MHC-specific and E7-MHC-specific single-do...
|
|
WO/2024/048657A1 |
Provided is a method for treating lymphoma. The present invention uses a pharmaceutical composition that is for treating lymphoma and comprises BCV, a pharmaceutically acceptable salt thereof, or a solvate of these. The lymphoma may be E...
|
|
WO/2024/048490A1 |
[Problem] It is desired to develop a molecule that maintains antitumor activity and offers excellent safety. It is also desired to develop an antibody-drug conjugate that can be administered systemically and delivers a STING agonist spec...
|
|
WO/2024/046622A1 |
The invention lies in the field of delivery of nucleic acids into a cell. In particular, disclosed herein is a nucleic acid that is polyplexed with a polymeric scaffold, which is provided in combination with an endosomal escape-enhancing...
|
|
WO/2024/049792A1 |
A method of treating cancer in a subject is provided, the method including administering to the subject a therapeutic amount of a composition including phosphatidylglycerol nanovesicles (NVs). A method of inhibiting M2 macrophage polariz...
|
|
WO/2024/047114A1 |
Disclosed herein are recombinant non-oncolytic viruses, for example adenoviruses, that encode bispecific T cell engagers (BiTE's). These BiTE's can be expressed at any desired site of the human body. The non-oncolytic viruses are able to...
|
|
WO/2024/049922A1 |
Disclosed herein are methods for treating cancer comprising administering to a subject a daily dose of Compound A, or a pharmaceutically acceptable salt thereof, as a single agent.
|
|
WO/2024/046443A1 |
Provided herein are macrocyclic compounds, pharmaceutical compositions, and methods of using related to cyclin dependent kinases (CDKs). The compounds herein are selective CDK2 inhibitors, which can be used for treating cancer.
|
|
WO/2024/050297A1 |
Described herein are compounds that are inhibitors of autophagy and their use in the treatment of disorders such as cancers.
|
|
WO/2024/050515A1 |
The present disclosure relates to methods of treating prostate cancer in a subject by co-administering to the subject an effective amount of: (i) an androgen receptor signaling inhibitor (ARSI) (e.g., abiraterone); and (ii) an anti-Trop-...
|
|
WO/2024/047218A1 |
Described herein are compositions and methods to produce masked antibodies useful in a variety of therapeutic indications.
|
|
WO/2024/046405A1 |
Provided is use of a compound represented by formula (I) or a pharmaceutically acceptable salt thereof in treating advanced or metastatic NSCLC.
|
|
WO/2024/047130A1 |
Relaxin-2 for use as a broad-spectrum substitute of glucocorticoids, mineralocorticoids, corticosteroids and their analogues for treating tissue and endothelial injuries without incurring inducing gluconeogenesis, Cushing's syndrome and ...
|
|
WO/2024/047110A1 |
The present invention relates to a new method to obtain more effective CAR-T cells. Here, the inventors worked on the function of FOXO1 in T lymphocyte physiology for many years. They recently described, using a FOXO1 pharmacological inh...
|
|
WO/2024/050296A2 |
The present disclosure is directed to methods of inhibiting clonal hematopoiesis in a subject by administering a senolytic agent.
|
|
WO/2024/046327A1 |
Compounds represented by formula I, and racemates, stereoisomers, tautomers, isotope-labeled substances, nitrogen oxides, solvates, polymorphs, pharmaceutically acceptable salts or prodrugs thereof. The compounds have a good inhibition e...
|
|
WO/2024/046332A1 |
Provided is a pharmaceutical composition, comprising: (a) a targeting agent against cancer cell mitochondria, (b) an ion chelating agent, and (c) a pharmacologically active multivalent ion. On the basis of the total weight of the pharmac...
|
|
WO/2024/050351A1 |
Described herein are compounds that are inhibitors of autophagy and their use in the treatment of disorders such as cancers.
|
|
WO/2024/049306A1 |
This disclosure provides compounds, including chemical conjugates, and compositions comprising these, as well as kits, which are useful in therapeutic and diagnostic procedures, amongst others. This disclosure also provides preparative m...
|
|
WO/2024/050396A1 |
The disclosure provides methods of treating cancers that have activating FGFR3 gene alterations by administering a compound of Formula (I) as disclosed herein, or a pharmaceutically acceptable salt of a compound of Formula (I).
|
|
WO/2024/048687A1 |
The present invention provides a pharmaceutical composition that contains an MYT1 inhibitor as an active ingredient, that is for therapy or prevention of cancer in a patient exhibiting RB1 functional deterioration, and that is to be used...
|
|
WO/2024/046406A1 |
Provided herein are certain alkylidenyl carbamate compounds that inhibit certain K-Ras proteins and are therefore useful for the treatment of cancers mediated by such proteins. Also provided are pharmaceutical compositions containing suc...
|
|
WO/2024/046370A1 |
The present invention relates to compounds of formula (I) and formula (II), or pharmaceutically acceptable salts, prodrugs, tautomers, or stereoisomers and solvates thereof. Said compounds can be used for the treatment of cancers and inf...
|
|
WO/2024/049220A1 |
The present invention relates to an immunoconjugate or a pharmaceutically acceptable salt thereof characterized in that a camptothecin-based drug (A) is bound, through a linker (C), to: an antibody or an antigen-binding fragment (B-1) th...
|
|
WO/2024/045503A1 |
Disclosed is a TRKA (G667C), FLT3 and FLT3 (D835Y) target inhibitor N-[4-(6-fluoro-1H-2-benzimidazolyl)benzyl]-(E)-3-(3-pyridine
)acrylamide as shown in formula (I), a preparation method therefor, a pharmaceutical composition containing ...
|
|
WO/2024/050267A1 |
The present disclosure is directed to oligonucleotide dendrons comprising an oligonucleotide stem linked to one or more oligonucleotide branches. The disclosure also provides methods of using the oligonucleotide dendrons.
|
|
WO/2024/015757A9 |
Provided herein is a combination therapy for use in a method of treating mantle cell lymphoma in a patient in need thereof.
|
|
WO/2024/044825A1 |
Provided herein are collections of compounds of formula a) to u), and salts thereof, which have polycyclic aromatic scaffolds and thus have structures targeted towards binding polynucleotide therapeutic targets, including polynucleotide-...
|
|
WO/2024/050433A1 |
Small molecule allosteric modulators of androgen receptor are disclosed. The compounds may inhibit androgen receptor coactivator recruitment, such as by preventing formation of protein-protein interaction (PPI) complexes and/or disruptin...
|
|
WO/2024/049931A1 |
The present disclosure is directed to alcohol and amine containing exatecan derivatives, and pharmaceutically acceptable salts or solvates thereof, comprising a structure of formula (I): wherein X is defined in the disclosure. The disclo...
|
|
WO/2024/048809A1 |
The present invention relates to a novel heteroaryl derivative compound containing N, a method for preparing same, a pharmaceutical composition comprising same as an active ingredient, and use thereof. The compound of the present inventi...
|
|
WO/2024/046394A1 |
Provided are a TIGIT and OX40-based strengthened receptor (TIGIT/OX40) capable of increasing the activation level and survival time of immune cells, and an immune cell modified to express the strengthened receptor. Also provided is an im...
|
|
WO/2024/047135A1 |
Provided herein are compounds identified as inhibitors of KRAS protein activity that can be used to treat various diseases and disorders, such as cancer.
|
|
WO/2024/050078A1 |
Provided herein are heterocyclic phenyl compounds useful as degraders of KAT2, as well as compositions and methods of use thereof.
|
|
WO/2024/046457A1 |
Provided are a triazine compound of formula (I), a pharmaceutical composition comprising same, a preparation method therefor and the use thereof.
|
|
WO/2024/046245A1 |
Disclosed are an anti-human PVRIG antibody or an antigen-binding fragment thereof, as well as an application thereof in the preparation of a medicament for treating diseases, such as cancer, which are related to the abnormal expression o...
|
|
WO/2024/048542A1 |
This medicament, which contains, together or separately in combination with a PARP inhibitor, an antibody or a fragment thereof having an immunological reactivity with a CAPRIN-1 protein, is useful for treating and/or preventing cancer.
|
|
WO/2024/044821A1 |
The invention relates to methods for determining or predicting prognosis for and survival of a subject with prostate cancer, the methods comprising determining the level of at least three lipid biomarkers in a biological sample obtained ...
|
|
WO/2024/049948A1 |
Disclosed herein are methods of treating cancer. More specifically, this disclosure provides methods for treating cancer in a subject using compounds that are inhibitors of PRMT5, particularly in combination with a BCL-2 family inhibitor.
|
|
WO/2024/049164A1 |
One aspect relates to nanovesicles for delivering cell membrane-derived nucleic acids and a method for preparing same. The nanovesicles according to one aspect are derived from cell membranes and have no immune response or toxicity, are ...
|
|
WO/2024/047811A1 |
Provided is a method for treating lymphoma. Use is made of a composition for treating lymphoma, the composition containing BCV, a pharmaceutically acceptable salt thereof, or a solvate of the BCV or the salt thereof. The lymphoma may b...
|
|
WO/2024/046407A1 |
Provided is use of a heteroaryloxynaphthalene compound, in particular, use of compound A or a pharmaceutically acceptable salt thereof in preparing a medicament for treating a tumor-related disease. Compound A or the pharmaceutically acc...
|
|
WO/2024/046322A1 |
The present disclosure provides agonistic IL-15 complexes that have therapeutic use, and methods for making such proteins. The present disclosure additionally provides methods of treating disease in a subject in need thereof by administe...
|
|
WO/2024/046366A1 |
The present invention provides a selective PARP1 inhibitor. Specifically, the present invention provides a compound or a pharmaceutically acceptable salt or solvate thereof, wherein the compound is represented by formula A, and the group...
|
|
WO/2024/050466A1 |
The present disclosure provides methods for treating or inhibiting the growth of MET associated non-small cell lung cancer comprising selecting a subject with cancer and administering a therapeutically effective amount of a MET x MET bis...
|
|
WO/2024/045066A1 |
Provided are certain alkylidenyl carbamate compounds that inhibit certain K-Ras proteins and are therefore useful for the treatment of cancers mediated by such proteins. Also provided are pharmaceutical compositions containing such compo...
|
|
WO/2024/050426A2 |
The present invention provides methods and compositions for treating cancers, as well as methods for increasing an immune response against a tumor, in a subject in need thereof by decreasing the expression and/or activity of Stub1 in an ...
|
